Drug-eluting stents for PAD, what does (all) the data tell us?

Drug-eluting stents for PAD, what does (all) the data tell us? J Cardiovasc Surg (Torino). 2019 Apr 30;: Authors: Phillips J Abstract When the FDA approved the use of a paclitaxel-coated stent in the peripheral arteries in November of 2012, a new era in the treatment of peripheral arterial disease (PAD) emerged. This marked, for the first time in the United States, that a drug-eluting device was available to treat this complex arterial bed, and has likely changed forever how PAD is treated. Prior to this, US physicians had been using drug-eluting stents (DES) in the coronary arteries for 8 years with exceptional results in both safety and efficacy. Since the Zilver®PTX® (Cook Medical, Bloomington, IN USA) was released, multiple drug-coated balloons (DCB) with paclitaxel have been approved in the US, as has another DES, the EluviaTM stent (Boston Scientific, Minneapolis, MN USA). PMID: 31058479 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: J Cardiovasc Surg (Torino) Source Type: research